课题基金 / 基金详情

Promoting Smoking Cessation in Lung Cancer Screening through Proactive Treatment

Promoting Smoking Cessation in Lung Cancer Screening through Proactive Treatment
通过积极治疗促进肺癌筛查中戒烟
批准号:
10197054
负责人:
Steven Bacchus Zeliadt
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-01 至 2022-02-28

项目摘要

项目成果

Steven Bacchus Zeliadt的其他基金

相似基金

相关文献

中文摘要
翻译
通过积极治疗促进肺癌筛查中的戒烟:PRACT 退伍军人医疗中心开始提供符合条件的退伍军人肺癌筛查 建议包括美国预防服务工作组的年度B建议 放映。退伍军人事务部肺癌筛查示范项目的初步证据表明 近280万退伍军人将有资格进行筛查,超过一半的人将是长期吸烟者 吸烟史。至关重要的是,为目前的吸烟者提供筛查加强了 戒烟并不会减少戒烟的动力。将戒烟纳入肺癌筛查 具有挑战性,部分原因是时间和临床资源有限,但也是因为对 筛查在许多当前吸烟者中的“保护性”作用。在国家肺部筛查试验中,初级 提供筛查的护理提供者充分解决了戒烟问题,目前只有10%的吸烟者。 该项目将为所有当前吸烟者提供积极的行为和药物治疗,作为 参与肺癌筛查。烟草治疗将与筛查报告相结合 结果。在我们对拟议干预的主动电话咨询部分进行的试点研究中,我们 干预参与者中行为戒断治疗的参与率从11%提高到36% 在常规护理控制的患者中,干预组的戒烟率增加了一倍多,达到18%。 筛查患者经常报告说,他们有参与筛查的动机,以了解吸烟量 伤害了他们。我们提议的干预措施旨在将这种新的患者参与度转化为 鼓励戒烟的机会。我们提出的主动护理策略消除了询问的前提 病人如果他们准备好戒烟的话。超过14项试验表明,为所有当前吸烟者提供选择戒烟治疗 显著提高了戒烟率。 我们将在弗吉尼亚州普吉特湾和弗吉尼亚州纽约港对目前的吸烟者进行务实的随机试验 都在参与肺癌筛查。患者将被随机分成两组,分别接受主动护理和OPT- 随筛查结果出院治疗(n=250)或常规护理(n=250)。积极的治疗将是 由放射学协调员安排,并将包括一封量身定做的结果信,描述 药物治疗,与患者的初级保健提供者一起订购的适当处方, 以及两次积极主动的电话行为咨询会议。电话咨询组件将 由退伍军人管理局全国戒烟热线的顾问提供。主要终点是经过生化确认的7天 筛查后12个月禁欲。基于先前的选择退出治疗试验和我们的试点数据,试验是 有能力检测戒烟率从通常护理的9%提高到选择退出治疗的至少18%。
英文摘要
Promoting smoking cessation in lung cancer screening through proactive therapy: PROACT VA Medical Centers are beginning to offer eligible Veterans lung cancer screening following national recommendations including the US Preventive Services Task Force's “B” recommendation for annual screening. Preliminary evidence from the VA Lung Cancer Screening Demonstration Project suggests that nearly 2.8 million Veterans will be eligible for screening and over half will be current smokers with a long history of smoking. It is critical that offering screening to current smokers reinforces the importance of cessation and does not reduce motivation to quit. Integrating cessation into lung cancer screening is challenging, in part because of limited time and clinic resources, but also because of misperceptions about the “protective” effect of screening among many current smokers. In the National Lung Screening Trial, primary care providers offering screening adequately addressed smoking cessation with only 10% of current smokers. This project will provide proactive behavioral and pharmacotherapy treatment to all current smokers as part of participating in lung cancer screening. Tobacco treatment will be integrated with the reporting of screening results. In our pilot study of the proactive telephone counseling component of the proposed intervention, we increased participation in behavioral cessation treatment to 36% among intervention participants from 11% among usual care control patients, and quit rates more than doubled to 18% in the intervention group. Screening patients often report being motivated to participate in screening to find out how much smoking has harmed them. Our proposed intervention is designed to convert this new level of patient engagement into an opportunity to encourage cessation. Our proposed proactive care strategy removes the precondition of asking patients if they are ready to quit. Over 14 trials have shown providing opt-out treatment to all current smokers significantly increases quit rates. We will conduct a pragmatic randomized trial with current smokers at VA Puget Sound and VA NY Harbor who are participating in lung cancer screening. Patients will be randomized to receive either proactive care with opt- out treatment accompanying their screening results (n=250) or usual care (n=250). Proactive treatment will be arranged by a radiology-based coordinator, and will include a tailored results letter describing pharmacotherapy, an appropriate prescription ordered in conjunction with the patient's primary care provider, and two proactive telephone-based behavioral counseling sessions. The telephone counseling component will be delivered by counselors at VA's national quitline. The primary endpoint is biochemically confirmed 7-day abstinence 12 months after screening. Based on prior trials of opt-out treatment and our pilot data, the trial is powered to detect an improvement in quit rates from 9% with usual care to at least 18% with opt-out treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Promoting Smoking Cessation in Lung Cancer Screening through Proactive Treatment
  • 批准号:
    9293001
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    Steven Bacchus Zeliadt
  • 依托单位:
Promoting Smoking Cessation in Lung Cancer Screening through Proactive Treatment
  • 批准号:
    10290892
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    Steven Bacchus Zeliadt
  • 依托单位:
Semi-parametric Statistical Methods for Predicting High-cost VA Patients Using High-Dimensional Covariates
  • 批准号:
    10186525
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    Steven Bacchus Zeliadt
  • 依托单位:
Semi-parametric Statistical Methods for Predicting High-cost VA Patients Using High-Dimensional Covariates
  • 批准号:
    9695867
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    Steven Bacchus Zeliadt
  • 依托单位:
海外基金